News
Five takeaways from the new donanemab data
Headlines about the results of TRAILBLAZER-ALZ2 trial of Eli Lilly’s Alzheimer’s drug candidate donanemab are spreading around the world, with some going as far as to sugg
Thursday 1 June 2023
